Close sees potential in cancer tech firm

Close has invested £1.4m while London Technology Fund is also now a shareholder.

Dexela develops 3D imaging technology, known as tomosynthesis, that’s used to detect breast cancer. The technology allows for earlier detection and reduces the need for patient callbacks.

On its website, Dexela says the market for digital mammography is expected to exceed $1bn within the next few years and that tomosynthesis will dominate the market in the next five years.

Dexela was founded in 2005 by Ed Bullard. It is headquartered in London but has a R&D facility in Sudbury, Massachusetts Commenting on the funding round, Bullard says: “Close Ventures has clearly demonstrated its thorough understanding of what we are trying to achieve and how to develop the business.”

Picture source

Share this story

Send this to a friend